Ebola is the life-threatening epidemic that was brought to light in the year 2014 when it spread across the West African region. Ebola is a viral infected disease that causes fever followed by massive internal bleeding. It is a contagious disease that extends through contact with the infected person. The need of the hour is to control the situation by with the advent of Ebola virus vaccine and save the lives of thousands affected with the fatal disease. The research and study on Ebola virus vaccine is moving at a past pace and every day the researchers at etching closer to the big discovery. Globally, numerous research centers are closely studying the virus and conducting research to discover the right antidote for the viral infection.
The Vaccine Research Center (VRC), in association with Okairos, a Swiss-Italian biotech company that was recently acquired by GSK, has devised a candidate for Ebola vaccine. The VRC scientists have designed some vaccine after undertaking massive research and study on the subject. The investigational vaccines do not comprise any infectious Ebola virus material. Two Ebola genes have been inserted in this chimpanzee adenovirus vector vaccine. They have successfully created a non-replicating viral vector. This vaccine enters a cell, transports the gene inserts and ensures it refrains from replicating further. The immune system quickly adapts to the vaccine and reacts positively. The VRC vaccine is soon scheduled to enter into a phase 1 clinical trial after attaining the pending approval by the FDA. Besides, the VRC has also initiated talks with governmental and non-governmental partners to explore the opportunities in progressing this promising vaccine candidate beyond the Phase I clinical evaluation. Many other small research studies being conducted on the vaccine involving about 260 people in Switzerland, United Kingdom and Mali.
Research studies are primarily conducted to ensure the vaccine is efficient, safe and approved by health ministries. Numerous experimental vaccine have been developed and yet in testing stages. These crucial studies will be soon produced with the summary of all the significant findings. This data will be further used to plan the next set of actions to be taken against Ebola. It aims to provide trials to clarify the amount of dose of the vaccine required to trigger the desired effect on the immune system and attain responses. Studies are also being conducted to ensure there no additional side effects of the vaccine on human body.
Note- This information is researched on behalf of material is present on Internet, We as content publishing team for Bioxcel clarify this not our own researched data. We are hoping to update you soon with some good news in future.
No comments:
Post a Comment